Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 10

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 10
---
 our listing on The Nasdaq Capital Market at this time, nor are our business operations affected by receipt of the Notification Letter. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until December 18, 2025, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification Letter to evidence compliance. We are looking into various options available to regain compliance and maintain our continued listing on The Nasdaq Capital Market. There can be no assurance that our plan will be accepted or we will be able to regain compliance with the Minimum Stockholders’ Equity Rule. As previously announced, on September 17, 2025, we entered into securities purchase agreements, or the SPAs, with investors, or the CLA Investors, pursuant to which we shall issue and sell, from time to time, convertible promissory notes, or the Promissory Notes, in the aggregate principal amount of up to $10,000,000, or the Subscription Amount. As of the date hereof, we have issued Promissory Notes in the aggregate principal amount of $2.5 million. As of the date hereof, all the outstanding amounts due under the Promissory Notes were converted into 5,171,460 Common Shares. In addition, on November 13, 2025, we raised approximately $0.788 million in a registered direct offering of common shares and pre-funded warrants, on November 17, 2025, we raised approximately $1.377 million in a registered direct offering of common shares and pre-funded warrants, on November 19, 2025, we raised approximately $2.185 million in a registered direct offering of common shares, on November 26, 2025 we raised approximately $1.294 million in a registered direct offering of common shares and pre-funded warrants and on December 3, 2025, we raised approximately $1.6 million in a registered direct offering of common shares (see “Recent Developments—November 2025 Registered Direct Offerings” and “Recent Developments—December 2025 Registered Direct Offering” below for additional information), and as of December 2, 2025, we issued 2,090,987 common shares as a result of the exercises for cash and on a cashless basis of warrants to purchase 2,894,769 common shares, which were previously classified as a liability given certain of